In contrast, an in vitro study showed that FoxO1 overexpression reduces Aβ production and tau phosphorylation, suggesting that FOXO1 could be a novel target for AD treatment (Zhang et al., 2020). This evidence concerns the gene FOXO1 and Alzheimer disease.